| |
CEE + MPA trial
|
|---|
| |
Placebo
|
Active treatment
|
|---|
| |
Cases
|
Controls
|
P-value*
|
Cases
|
Controls
|
P-value*
|
|---|
|
Estradiol (pg/ml)
| | | | | | |
|
Baseline
|
11.97 (4.96, 28.84)
|
10.05 (4.36, 23.17)
|
0.001
|
10.90 (4.83, 24.59)
|
10.89 (4.19, 28.34)
|
0.99
|
|
Year 1
|
10.12 (3.56, 28.71)
|
8.46 (2.86, 25.02)
|
0.008
|
22.30 (7.88, 63.06)
|
20.78 (6.02, 71.72)
|
0.28
|
|
Bioavailable estradiol (pg/ml)
| | | | | | |
|
Baseline
|
8.02 (2.89, 22.25)
|
6.47 (2.49, 16.85)
|
0.001
|
7.10 (2.71, 18.60)
|
7.00 (2.31, 21.16)
|
0.82
|
|
Year 1
|
6.75 (2.16, 21.06)
|
5.35 (1.52, 18.76)
|
0.002
|
9.95 (3.75, 26.38)
|
9.98 (3.14, 31.71)
|
0.96
|
|
Estrone (pg/ml)
| | | | | | |
|
Baseline
|
41.81 (17.36, 95.94)
|
35.20 (14.99, 82.68)
|
0.007
|
36.95 (16.06, 85.03)
|
36.37 (15.79, 83.74)
|
0.74
|
|
Year 1
|
37.68 (13.99, 101.49)
|
34.39 (13.78, 85.81)
|
0.14
|
117.48 (30.97, 445.66)
|
103.96 (23.00, 469.86)
|
0.14
|
|
Estrone sulfate (ng/ml) baseline
|
0.84
|
0.79
|
0.26
|
0.82
|
0.80
|
0.65
|
| |
(0.37, 1.91)
|
(0.33, 1.88)
| |
(0.33, 2.08)
|
(0.29, 2.18)
| |
|
Year 1
|
0.75 (0.34, 1.67)
|
0.69 (0.30, 1.59)
|
0.17
|
1.88 (0.61, 5.81)
|
1.77 (0.51, 6.14)
|
0.37
|
|
SHBG (Nmol/L)
| | | | | | |
|
Baseline
|
36.93 (15.05, 90.63)
|
41.94 (17.28, 101.80)
|
0.02
|
40.49 (14.99, 109.42)
|
39.81 (14.63, 108.31)
|
0.76
|
|
Year 1
|
37.37 (14.22, 98.23)
|
41.86 (16.51, 106.11)
|
0.06
|
95.46 (31.96, 285.11)
|
90.07 (30.96, 262.06)
|
0.35
|
- Samples are excluded if changes from baseline to year 1 log-transformed concentrations are outside the interquartile range by twice its width.
- *P-value from Student’s t-test comparison of case versus control values. CEE, conjugated equine estrogens; MPA, medroxyprogesterone acetate; SHBG, sex hormone binding globulin.
